ArticlePloS one2025
Risk of hepatitis B virus reactivation in the treatment of HBsAg and HBV DNA double-negative lymphoma patients.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt is well-known that lymphoma patients undergoing treatment are at risk of hepatitis B virus (HBV) reactivation. This study aims to explore the risk factors for HBV reactivation in lymphoma patients who tested negative for both hepatitis B surface antigen (HBsAg) and HBV DNA before treatment, during their course of therapy. It provides clinical evidence for early intervention in HBV reactivation and rational preventive antiviral treatment.
methodsFrom January 2019 to December 2021, a total of 1,229 patients were diagnosed with lymphoma at Guangdong Provincial People's Hospital. Among them, 616 patients who tested negative for both HBsAg and HBV DNA and underwent therapy were recruited for the study. The recruited patients had a median age of 53.9 years (range: 14-88 years), with 358 males (58.12%) and 258 females (41.88%). The risk factors associated with HBV reactivation in these patients were then analyzed.
resultsAmong the 616 lymphoma patients enrolled in this study, 44 patients (7.14%, 44/616) exhibited HBV reactivation. Notably, the rate of HBV reactivation was significantly higher in patients with hepatitis B core antibody (HBcAb) (+) (10.00%) compared to those with HBcAb (-) (1.46%) (P < 0.001, OR = 7.52). An analysis of HBV reactivation rates across different age groups demonstrated a statistically significant difference (P = 0.002). In particular, patients aged over 60 years showed a markedly elevated rate of HBV reactivation compared to those in other age brackets (P < 0.001). Conversely, no statistically significant differences in HBV reactivation rates were observed between patients of different genders (P = 0.637, OR = 0.855) or across varying treatment durations (P = 0.851).
conclusionFor lymphoma patients undergoing treatment, HBV reactivation may occur even if both HBsAg and HBV DNA are negative at the initiation of treatment. It is noteworthy that this study found that patients with HBcAb (-) also experienced HBV reactivation. Therefore, patients who are negative for HBsAg, HBcAb, and HBV DNA should also be closely monitored to mitigate the risk of HBV reactivation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.